<DOC>
	<DOC>NCT02881346</DOC>
	<brief_summary>This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany,</brief_summary>
	<brief_title>Efficacy and Tolerability of Enstilar® in Daily Practice</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>≥ 18 years of age Psoriasis vulgaris Lesions on trunk and/or extremities of at least mild severity Treatment with Enstilar® planned Signed informed consent to participate Enrolled in any interventional clinical trial Ongoing or recent treatment with any systemic psoriasis Ongoing or recent treatment with UVtherapy Ongoing or previous treatment with Enstilar® Psoriasis of scalp only Other forms of psoriasis, e.g. erythrodermic or pustular psoriasis More than 30% of surface area affected by psoriasis Any contraindications or known allergies to Enstilar® or its ingredients Incapacitated patients under institutionalized care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriasis vulgaris</keyword>
	<keyword>Plaque</keyword>
	<keyword>Topical</keyword>
	<keyword>Calcipotriol</keyword>
	<keyword>Foam</keyword>
	<keyword>Spray</keyword>
</DOC>